Vision care is a blind spot.
Stare Down
An extension of the brain, the eyes offer a window into overall health, with annual exams capable of flagging >270 systemic diseases early — from diabetes and hypertension to high cholesterol, cancer, MS, and stroke.
Overlooked, nearly half of Americans say vision care doesn’t feel urgent, and 66% think degeneration is inevitable, but early intervention can delay or prevent permanent damage.
Nearsightedness is up 16% since the ’70s, and 93M US adults have high risk of vision loss, yet just half regularly see an eye doctor, driving reactive care costs up to $373B by 2050.
Eye Robot
Empowered by AI breakthroughs, experts are advancing “Oculomics” — using imaging to translate ocular biomarkers into whole-body insights.
Spot check. Point-of-care solutions, AEYE Health and Oivi’s autonomous tabletop devices let non-specialized physicians screen for eye-related conditions on the spot.
Accelerating adoption, Optain Health added $26M last year to roll out portable retinal cameras across seven US health systems, while Eyebot landed $20M for autonomous retail kiosks.
Entering medtech, Ray-Ban owner EssilorLuxottica scooped up European ophthalmology clinic operator Signifeye. Deploying across Norway’s national health system, Eyenuk’s tech is being used to tackle diabetic retinopathy.
Strained. Autonomous scans could fill care gaps, exposing links to overall health and improving accessibility for those without vision coverage.
Decoding biological age, Toku’s AI eye exams are integrated with Lifeforce’s longevity platform. Checking eyes for CVD, South Korea’s Mediwhale shows comparable results to a CT, while Google’s AI outperforms clinicians in predicting age-related macular degeneration.
Targeting neurological conditions, RetiSpec’s test tracks Alzheimer’s, and JuneBrain is developing a telehealth eye-scanning headset for remote monitoring.
Double-take. On the corrective side, IXI is readying autofocusing glasses, while VIZZ’s FDA-approved eye drops clear vision for 10 hours.
An invisible diagnostics play, Dubai’s XPANCEO raised $250M at a $1.35B valuation, plotting smart contacts that combine tear-based health tracking, AR, and vision enhancement by 2030.
Takeaway: Like the skin, microbiome, and menstrual blood, the eyes have underexplored diagnostic potential. As AI models learn from mass data, simple scans could predict an array of systemic diseases before they’re irreversible, becoming a common entry point to care.
